QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
Log in
NASDAQ:ATRS

Antares Pharma Stock Forecast, Price & News

$2.86
-0.02 (-0.69 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.85
Now: $2.86▼
$2.92
50-Day Range
$2.73
MA: $3.01▼
$3.37
52-Week Range
$1.60
Now: $2.86▼
$5.13
Volume822,060 shs
Average Volume1.22 million shs
Market Capitalization$476.68 million
P/E Ratio47.67
Dividend YieldN/A
Beta1.44
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Read More
Antares Pharma logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.97 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
Previous Symbol
CUSIP03664210
CIK1016169
Webwww.antarespharma.com
Phone609-359-3020
Employees178

Debt

Debt-to-Equity Ratio0.53
Current Ratio2.47
Quick Ratio2.08

Price-To-Earnings

Trailing P/E Ratio47.67
Forward P/E Ratio47.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$123.86 million
Price / Sales3.85
Cash Flow$0.00 per share
Price / Cash Flow886.97
Book Value$0.39 per share
Price / Book7.33

Profitability

EPS (Most Recent Fiscal Year)($0.01)
Net Income$-2,030,000.00
Net Margins6.64%
Return on Equity16.48%
Return on Assets6.69%

Miscellaneous

Outstanding Shares166,672,000
Market Cap$476.68 million
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable
$2.86
-0.02 (-0.69 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

How has Antares Pharma's stock been impacted by COVID-19 (Coronavirus)?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATRS shares have decreased by 4.7% and is now trading at $2.86.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Antares Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Antares Pharma.

What stocks does MarketBeat like better than Antares Pharma?

Wall Street analysts have given Antares Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Antares Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Antares Pharma.

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) issued its earnings results on Tuesday, November, 10th. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01. Antares Pharma had a net margin of 6.64% and a return on equity of 16.48%.
View Antares Pharma's earnings history.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma updated its FY 2020 Pre-Market earnings guidance on Thursday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $140.95 million.

What price target have analysts set for ATRS?

4 brokers have issued twelve-month price targets for Antares Pharma's shares. Their forecasts range from $4.50 to $7.00. On average, they anticipate Antares Pharma's share price to reach $5.63 in the next twelve months. This suggests a possible upside of 96.7% from the stock's current price.
View analysts' price targets for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Some companies that are related to Antares Pharma include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Meridian Bioscience (VIVO) and Anika Therapeutics (ANIK).
View all competitors.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), Canopy Growth (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 54, Pay $1.01M)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 59, Pay $590.73k)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 53, Pay $613.48k)
  • Mr. Patrick Madsen, Sr. VP of Operations
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 57)
  • Mr. Edward Tykot, Sr. VP of Corp. Bus. Devel.
  • Dr. Peter Sadowski, Sr. VP of Technology Portfolio & Intellectual Property (Age 72)
  • Dr. Jonathan S. Jaffe, Interim EVP, Pharmaceutical R&D and Chief Medical Officer
  • Mr. Greg Defilippis, Sr. VP of Device Bus. & Alliances
  • Dr. Steven Knapp M.S. Pharm.D., Sr. VP of Regulatory Affairs & Quality Assurance

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.92%), State Street Corp (2.51%), Stonepine Capital Management LLC (0.72%), Charles Schwab Investment Management Inc. (0.61%), JPMorgan Chase & Co. (0.46%) and AQR Capital Management LLC (0.44%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma.

Which institutional investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., SG Americas Securities LLC, Squarepoint Ops LLC, Cubist Systematic Strategies LLC, AQR Capital Management LLC, JPMorgan Chase & Co., and Morgan Stanley. Company insiders that have sold Antares Pharma company stock in the last year include Marvin Samson, Robert F Apple, and Thomas J Garrity.
View insider buying and selling activity for Antares Pharma.

Which institutional investors are buying Antares Pharma stock?

ATRS stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Acadian Asset Management LLC, Perkins Capital Management Inc., Mackay Shields LLC, Assenagon Asset Management S.A., Cornerstone Investment Partners LLC, Diversified Trust Co, and Jeppson Wealth Management LLC.
View insider buying and selling activity for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.86.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $476.68 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 178 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.